A clinical study to evaluate the therapeutic efficacy of Safuf Zarishk in the management of Ishal Dimaghi (Diarrhoea dominant Irritable Bowel Syndrome)

Iritable Bowel Syndrome, also referred to as Functional Bowel Syndrome, is the cluster of symptoms including abdominal pain, bloating, diarrhoea, flatulence and constipation, in absence of any structural or inflammatory abnormalities . Since there are no reliable biological and structural markers that have been yet identified, the treatment therapy is assessed by the questionnaire. In the United states of America, it happens to be one of the top ten reasons for visits to the primary care physicians . Globally, about 10-20% of the adults and adolescents have symptoms in accordance with IBS symptoms . In the Kashmir valley, 24.9% of the general population is diagnosed with IBS . The global prevalence of IBS-D is 31.5% with ROME IV criteria The usual pharmacological treatment approach is on reducing symptom severity and the drugs used usually come with a lot of side effects. Also, less than one-third of IBS patients are satisfied with their present therapy, and 34% of them report no symptom management, therefore more potent treatments are neededThere needs to be the validation of more number of the safe and efficient unani drugs that act upon on the symptoms and synergistically target upon the hypothetical multifactorial pathologies. This approach will result in a long term relief, improve the burden of IBS-D related symptoms and improve the quality of life. This study will aim upon the same facts and hence a trial on efficacy of the unani formulation Safu f Zarishk will be evaluated, primarily on the stool urgency and frequency and secondarily on global IBS - D symptoms